Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circulating DNA in Adult Patients With Metastatic Cancer

Not Applicable

• Conditions: Metastatic Cancer
• Interventions: Procedure: Blood samples

• Registration Number: NCT02666612
• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary

Monitoring of circulating endothelial cells (CEC and mature cells called progenitors called CEP) or circulating tumor cells (CTC) in adult patients with metastatic cancer, possibly treated with targeted therapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-08
• Study First Submitted: 2015-08-12
• Study First Submitted QC: 2016-01-27
• Study First Posted: 2016-01-28
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-25
• Last Update Posted: 2017-01-26
• Primary Completion: 2023-08
• Study Completion: 2023-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 2240

Inclusion Criteria

• Patients with metastatic solid tumor
• Age> 18 years
• Signed consent

Exclusion Criteria

• Patients with diseases associated with vascular lesions known.
• Patients protected by law, in accordance with Articles L1121-5 to L1121-8 of the Code of Public Health.
• Mental pathology that can interfere with the proper conduct of the study.
• Refusal of consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients with metastatic cancer	Blood samples	-

Primary Outcome Measures

Name	Time	Method
Measurement and characterization of CEC and CEP and circulaing DNA rate using flow cytometry	up to 2 years	Measurement and characterization of initial CEC and CEP circulaing DNA and their evolution under treatment

Trial Locations

Locations (1)

Gustave Roussy Cancer Campus Grand Paris; 🇫🇷 Villejuif, Val de Marne, France